[
  {
    "ts": null,
    "headline": "Back on the Radar: Prior Picks Offer Fresh Opportunity",
    "summary": "Periods of volatility often create the most compelling opportunities to revisit prior ideas with fresh perspective.  This week I focus on opportunities within communication services, healthcare, and consumer staples.  Netflix  was covered by George Glover last December.",
    "url": "https://finnhub.io/api/news?id=24ff608af11dc0183932d9821990f1c16aec09cc1d754c2fe0f10081d6003415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771429620,
      "headline": "Back on the Radar: Prior Picks Offer Fresh Opportunity",
      "id": 139137840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Periods of volatility often create the most compelling opportunities to revisit prior ideas with fresh perspective.  This week I focus on opportunities within communication services, healthcare, and consumer staples.  Netflix  was covered by George Glover last December.",
      "url": "https://finnhub.io/api/news?id=24ff608af11dc0183932d9821990f1c16aec09cc1d754c2fe0f10081d6003415"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Boston Scientific (BSX) EP Momentum And CHAMPION‑AF Data Overhang",
    "summary": "Boston Scientific recently reported fourth-quarter 2025 sales of US$5,286 million and net income of US$672 million, alongside 2026 guidance calling for double‑digit reported and organic net sales growth. At the same time, the company is facing heightened attention on its electrophysiology and atrial fibrillation portfolio, with new clinical trials such as OPTION‑EMEA and upcoming CHAMPION‑AF data potentially influencing how investors view its long-term growth mix. We’ll now explore how...",
    "url": "https://finnhub.io/api/news?id=762f00de59bc99184a62c17bed192f3d3b5a8b73a282a9a049f8696d478aa121",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771398541,
      "headline": "How Investors May Respond To Boston Scientific (BSX) EP Momentum And CHAMPION‑AF Data Overhang",
      "id": 139130673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific recently reported fourth-quarter 2025 sales of US$5,286 million and net income of US$672 million, alongside 2026 guidance calling for double‑digit reported and organic net sales growth. At the same time, the company is facing heightened attention on its electrophysiology and atrial fibrillation portfolio, with new clinical trials such as OPTION‑EMEA and upcoming CHAMPION‑AF data potentially influencing how investors view its long-term growth mix. We’ll now explore how...",
      "url": "https://finnhub.io/api/news?id=762f00de59bc99184a62c17bed192f3d3b5a8b73a282a9a049f8696d478aa121"
    }
  }
]